Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
2011-04-05
2011-04-05
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
C514S001100, C530S300000
Reexamination Certificate
active
07919118
ABSTRACT:
The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure:in-line-formulae description="In-line Formulae" end="lead"?—NH—(CH2)α—[O—(CH2)β]γ—Oδ—(CH2)ε—Y—in-line-formulae description="In-line Formulae" end="tail"?wherein α, β, γ, δ, and ε are each integers whose values are independently selected.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4677195 (1987-06-01), Hewick et al.
patent: 5006333 (1991-04-01), Saifer et al.
patent: 5278065 (1994-01-01), D'Andrea et al.
patent: 5283317 (1994-02-01), Saifer et al.
patent: 5292654 (1994-03-01), Yoshimura et al.
patent: 5378808 (1995-01-01), D'Andrea et al.
patent: 5441868 (1995-08-01), Lin
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5547933 (1996-08-01), Lin
patent: 5580853 (1996-12-01), Sytkowski
patent: 5614184 (1997-03-01), Sytkowski et al.
patent: 5618698 (1997-04-01), Lin
patent: 5621080 (1997-04-01), Lin
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5668110 (1997-09-01), Barrett et al.
patent: 5672662 (1997-09-01), Harris et al.
patent: 5677280 (1997-10-01), Barrett et al.
patent: 5683983 (1997-11-01), Barrett et al.
patent: 5747446 (1998-05-01), Sytkowski
patent: 5756349 (1998-05-01), Lin
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5919758 (1999-07-01), Sytkowski
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5955422 (1999-09-01), Lin
patent: 5986047 (1999-11-01), Wrighton et al.
patent: 6048971 (2000-04-01), Sytkowski et al.
patent: 6077939 (2000-06-01), Wei et al.
patent: 6083913 (2000-07-01), Dower et al.
patent: 6103879 (2000-08-01), Chaovapong et al.
patent: 6107272 (2000-08-01), Sytkowski
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6121238 (2000-09-01), Dower et al.
patent: 6153407 (2000-11-01), Sytkowski et al.
patent: 6211608 (2001-04-01), Raina et al.
patent: 6251864 (2001-06-01), Dower et al.
patent: 6333031 (2001-12-01), Olsson et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6465430 (2002-10-01), Dower et al.
patent: 6489293 (2002-12-01), Sytkowski et al.
patent: 6498155 (2002-12-01), Luengo et al.
patent: 6506362 (2003-01-01), Dower et al.
patent: 6531121 (2003-03-01), Brines et al.
patent: 6552008 (2003-04-01), Duffy et al.
patent: 6552167 (2003-04-01), Rose
patent: 6576235 (2003-06-01), Williams et al.
patent: 6583272 (2003-06-01), Bailon
patent: 6660843 (2003-12-01), Feige et al.
patent: 6783965 (2004-08-01), Sherman et al.
patent: 6784154 (2004-08-01), Westenfelder
patent: 6858630 (2005-02-01), Luengo et al.
patent: 7084245 (2006-08-01), Holmes et al.
patent: 7414105 (2008-08-01), Holmes et al.
patent: 7528104 (2009-05-01), Holmes et al.
patent: 2002/0015691 (2002-02-01), Greenwald et al.
patent: 2002/0037841 (2002-03-01), Papadimitriou et al.
patent: 2002/0052317 (2002-05-01), Itri et al.
patent: 2002/0115833 (2002-08-01), Burg et al.
patent: 2002/0160013 (2002-10-01), Olsson et al.
patent: 2002/0169128 (2002-11-01), Sigounas et al.
patent: 2002/0177166 (2002-11-01), Guthridge et al.
patent: 2003/0009018 (2003-01-01), Maeda et al.
patent: 2003/0012777 (2003-01-01), Sherman et al.
patent: 2003/0050269 (2003-03-01), Escary
patent: 2003/0104988 (2003-06-01), Brines et al.
patent: 2003/0120045 (2003-06-01), Bailon
patent: 2003/0125262 (2003-07-01), Kiessling et al.
patent: 2003/0134798 (2003-07-01), Brines et al.
patent: 2003/0166249 (2003-09-01), Williams et al.
patent: 2003/0191291 (2003-10-01), Kochendoerfer et al.
patent: 2004/0062746 (2004-04-01), Martinez et al.
patent: 2004/0126361 (2004-07-01), Saifer et al.
patent: 2004/0136952 (2004-07-01), Bhaskaran et al.
patent: 2005/0014240 (2005-01-01), Sherman et al.
patent: 2005/0176627 (2005-08-01), Cerami et al.
patent: 0 400 472 (1990-12-01), None
patent: WO 90/12874 (1990-11-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO-92/16555 (1992-10-01), None
patent: WO-96/40189 (1996-12-01), None
patent: WO 96/40749 (1996-12-01), None
patent: WO-96/40750 (1996-12-01), None
patent: WO-96/40772 (1996-12-01), None
patent: WO-98/25965 (1998-06-01), None
patent: WO 00/07629 (2000-02-01), None
patent: WO 00/12587 (2000-03-01), None
patent: WO-00/24770 (2000-05-01), None
patent: WO-00/24782 (2000-05-01), None
patent: WO-00/33881 (2000-06-01), None
patent: WO 01/38342 (2001-05-01), None
patent: WO 01/59078 (2001-08-01), None
patent: WO 01/91780 (2001-12-01), None
patent: WO-02/065988 (2002-08-01), None
patent: WO 03/002716 (2003-01-01), None
patent: WO-2004/014424 (2004-02-01), None
patent: WO 2004/030617 (2004-04-01), None
patent: WO 2004/060299 (2004-07-01), None
patent: WO 2004/060300 (2004-07-01), None
patent: WO 2004/100997 (2004-11-01), None
patent: WO-2004/101600 (2004-11-01), None
patent: WO-2004/101606 (2004-11-01), None
patent: WO-2004/101611 (2004-11-01), None
patent: WO-2004/108070 (2004-12-01), None
Abuchowski, A.,et al., “Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase,” J. Biol. Chem, vol. 252, pp. 3582-3586 (1977).
Beauchamp, C.O., et al., “A new procedure for the synthesis of polytheylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin”, Anal Biochem., vol. 131, pp. 25-33 (1983).
Chen, R.H., et al., “Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)”, Biochem. Biophys. Acta., vol. 660, pp. 293-298 (1981).
El-Sayed et al., “Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium”, Pharm. Res., 2001, 18:23-28.
Francis, G.E., et al., “PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques”, Int. J. Hematol, vol. 68, pp. 1-18 (1998).
Gestwicki et al., “Influencing receptor-ligand binding mechanisms with multivalent ligant architecture”, J. Amer. Chem. Soc., 2002, 124:14922-14933.
Johnson, D.L., et al., “Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity”, Chem. Biol., vol. 4, pp. 939-950 (1997).
Johnson et al., “Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1”, Biochemistry 37: 3699-3710 (1998).
Kita, Y., et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma”, Dr. Des. Deliv. vol. 6, pp. 157-167 (1990).
Klajnert et al., “Dendrimers: properties and applications”, Acta Biochimica Polonica, 2001, 48:199-208.
Knauf, M.J., et al., “Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers”, J. Biol. Chem., vol. 263, pp. 15064-15070 (1988).
Lee, J.W., et al., “Reduction of azides to primary amines in substrates bearing labile ester functionality. Synthesis of a PEG-solubilized, “Y”-shaped iminodiacetic acid reagent for preparation of folate-tethered drugs”, Org. Lett., vol. 1, pp. 179-181 (1999).
Ramakrishnan et al., “Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoeitin after single and multiple doses in healthy volunteers”, J. Clin. Pharmacol., 2004, 44:991-992.
Saifer, M.G., et al., “Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol”, Adv. Exp. Med. Biol. vol. 366, pp. 377-387 (1994).
Sasaki, et a
Holmes Christopher P.
Tumelty David
Yin Qun
Affymax, Inc.
Fish & Richardson P.C.
Kosar Andrew D
LandOfFree
Spacer moiety for poly (ethylene glycol) modified peptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spacer moiety for poly (ethylene glycol) modified peptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spacer moiety for poly (ethylene glycol) modified peptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739029